Analysis of 6 Healthcare Stocks With Strong Upward Momentum (2025-11-18)

On November 18, 2025, Benzinga published an article titled

highlighting Cardinal Health (NYSE:CAH), Abivax (NASDAQ:ABVX), Elanco Animal Health (NYSE:ELAN), Guardant Health (NASDAQ:GH), Medpace Holdings (NASDAQ:MEDP), and GeneDx Holdings (NASDAQ:WGS) [1]. The report cited earnings beats, regulatory approvals, and technical breakout patterns as key drivers of momentum in these stocks.

• Sector Performance
  : The healthcare sector posted a +0.877% gain on November 18, 2025, outperforming most sectors except energy (+3.25%) and utilities (+2.16%) [0].
• Individual Stock Performance
  : Three of the six stocks outperformed the healthcare sector average:
  • Medpace Holdings (MEDP): +0.87%
  • Elanco Animal Health (ELAN): +0.75%
  • Guardant Health (GH): +0.29%
• Sector Rotation
  : The article’s claim of a shift from tech to healthcare is partially supported by today’s market data, though healthcare is not the top-performing sector [0].

Stock Symbol	Current Price	Day Change	Market Cap	P/E Ratio (TTM)	Volume vs Avg
CAH	$206.01	-0.08%	$48.95B	31.07	46%
ABVX	$113.53	-0.08%	$8.58B	-31.62	65%
ELAN	$21.57	+0.75%	$10.72B	308.21	20%
GH	$96.75	+0.29%	$12.01B	-30.05	30%
MEDP	$590.86	+0.87%	$16.64B	41.35	26%
WGS	$129.53	-0.02%	$3.74B	1295.30	23%

Data sources: Real-time quotes [2-7]

• Direct Stocks
  : CAH, ABVX, ELAN, GH, MEDP, WGS.
• Subsectors
  : Pharmaceuticals (CAH), Biotech (ABVX), Animal Health (ELAN), Oncology Diagnostics (GH), Clinical Research (MEDP), Genome Testing (WGS).
• Related ETFs
  : Healthcare-focused ETFs like XLV (SPDR Health Care) or XBI (iShares Biotech) may benefit from momentum in these stocks.

1. Earnings Verification
   : Need to confirm Q3 2025 earnings details (e.g., Guardant Health’s 38% YoY revenue growth mentioned in the article).
2. Regulatory Updates
   : Validate FDA approval status for Guardant Health’s breast cancer diagnostic tool and Abivax’s Phase 3 trial results.
3. Long-Term Momentum
   : Analyze 5-day/10-day price trends to assess if today’s performance is part of a sustained upward trajectory.

• Valuation Risk
  : ELAN (P/E:308) and WGS (P/E:1295) have extremely high valuations, making them vulnerable to corrections if growth expectations are not met.
• Profitability Risk
  : ABVX and GH have negative EPS, indicating ongoing losses that may pressure stock prices if profitability is delayed.
• Liquidity Risk
  : Most stocks have lower trading volume today than their 30-day average (e.g., ELAN at 20% of avg volume), which could lead to price volatility.

1. Upcoming Earnings
   : Q4 2025 earnings releases for the six stocks.
2. Regulatory News
   : FDA decisions for diagnostic tools (GH, WGS) and drug trials (ABVX).
3. Sector Rotation
   : Continued shift from tech to healthcare as indicated by the article.

Note: This analysis is for informational purposes only and does not constitute investment advice.